We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Radiation Therapy Effective for Young Men with Prostate Cancer

By HospiMedica staff writers
Posted on 15 May 2006
For men under the age 55 with localized prostate cancer, external beam radiation may be an effective option instead of both conservative and more invasive treatments, according to a new study. More...


Published in the June 15, 2006, issue of the Journal Cancer, the study found that external beam radiation therapy is as successful in younger prostate cancer patients as it is in older patients with same stage, localized disease. The study is the first to assess the outcome of radiation in men under 55 years of age.

Age is a controversial issue in prostate cancer, with younger age at diagnosis thought to be linked with more aggressive disease and poorer prognosis. As a result, clinicians tend to recommend more aggressive treatments, such as radical prostatectomy, to younger patients, even those with local, non-metastatic disease. Older patients diagnosed with similar organ-limited disease, however, are provided with more alternatives, including external beam radiation therapy. Recent studies have shown that radiation therapy is effective in treating localized prostate cancer in elderly patients and in men under 65 years of age.

Andre Konski, M.D., clinical research director, radiation oncology department at the Fox Chase Cancer Center (Philadelphia, PA, USA), and colleagues compared how men 55 and under fared five years after diagnosis compared to men between 60 and 69 and men 70 and over, evaluating survival, disease progression, and whether blood tests for prostate-specific antigen (PSA) showed signs of disease recurrence.

All the men had localized prostate cancer and were treated with external beam radiation. They found no statistically significant differences in the outcomes of these three age groups after five years: 94%, 95%, and 87% of patients in each respective age category were alive five years after diagnosis; 96%, 97%, and 98% of patients in each respective age category were without metastatic disease; and 82%, 76%, and 70% of patients in each respective age category had no signs of disease recurrence according to blood tests.

Even though this study did not compare radiation to other therapies, "external beam radiation at appropriate dose levels has been shown to be equivalent to permanent prostate seed implant and radical prostatectomy in the treatment of patients with stage T1-2 prostate cancer,” reported the authors. Because younger men with localized disease respond as well as older men to radiation, the researchers suggest that this less-invasive treatment alternative should be considered for this patient population.


Related Links:
Fox Chase Cancer Center

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.